HomeCompareNRBO vs CL

NRBO vs CL: Dividend Comparison 2026

NRBO yields 84.75% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NRBO wins by $2.00M in total portfolio value
10 years
NRBO
NRBO
● Live price
84.75%
Share price
$2.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.05M
Annual income
$615,863.14
Full NRBO calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — NRBO vs CL

📍 NRBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNRBOCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NRBO + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NRBO pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NRBO
Annual income on $10K today (after 15% tax)
$7,203.39/yr
After 10yr DRIP, annual income (after tax)
$523,483.67/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, NRBO beats the other by $518,892.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NRBO + CL for your $10,000?

NRBO: 50%CL: 50%
100% CL50/50100% NRBO
Portfolio after 10yr
$1.04M
Annual income
$310,632.55/yr
Blended yield
29.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

NRBO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-20.1
Piotroski
0/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NRBO buys
0
CL buys
0
No recent congressional trades found for NRBO or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNRBOCL
Forward yield84.75%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$2.05M$40.8K
Annual income after 10y$615,863.14$5,401.96
Total dividends collected$1.79M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: NRBO vs CL ($10,000, DRIP)

YearNRBO PortfolioNRBO Income/yrCL PortfolioCL Income/yrGap
1← crossover$19,175$8,474.58$11,012$312.01+$8.2KNRBO
2$35,703$15,186.58$12,196$412.95+$23.5KNRBO
3$64,630$26,427.72$13,599$549.66+$51.0KNRBO
4$113,864$44,709.84$15,288$736.64+$98.6KNRBO
5$195,450$73,615.70$17,353$995.28+$178.1KNRBO
6$327,228$118,096.19$19,926$1,357.80+$307.3KNRBO
7$534,919$184,784.73$23,194$1,873.82+$511.7KNRBO
8$854,669$282,305.61$27,439$2,621.52+$827.2KNRBO
9$1,336,042$421,546.65$33,088$3,727.38+$1.30MNRBO
10$2,045,428$615,863.14$40,806$5,401.96+$2.00MNRBO

NRBO vs CL: Complete Analysis 2026

NRBOStock

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Full NRBO Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this NRBO vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NRBO vs SCHDNRBO vs JEPINRBO vs ONRBO vs KONRBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.